Benzylamines

Home
About
Help
History (1)
- Benzylamines
- See All Pages

"Benzylamines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group.

Descriptor ID	D001596
MeSH Number(s)	D02.092.200 D02.455.426.559.389.140.210
Concept/Terms	Benzylamines Benzylamines alpha-Aminotoluene alpha-Aminotoluene alpha Aminotoluene Phenylmethylamine Phenylmethylamine

Below are MeSH descriptors whose meaning is more general than "Benzylamines".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amines [D02.092]
Benzylamines [D02.092.200]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Benzyl Compounds [D02.455.426.559.389.140]
Benzylamines [D02.455.426.559.389.140.210]

Below are MeSH descriptors whose meaning is related to "Benzylamines".

Below are MeSH descriptors whose meaning is more specific than "Benzylamines".

Benzylamines
Pargyline

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Benzylamines" by people in this website by year, and whether "Benzylamines" was a major or minor topic of these publications.

Bar chart showing 24 publications over 14 distinct years, with a maximum of 6 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	1	2
2003	0	2	2
2005	0	1	1
2006	0	1	1
2008	0	1	1
2009	0	3	3
2010	0	1	1
2013	0	1	1
2015	0	1	1
2018	0	1	1
2021	2	0	2
2022	1	0	1
2024	0	6	6
2025	0	1	1

Below are the most recent publications written about "Benzylamines" by people in Profiles.

Ezenna C, Krishna MM, Joseph M, Pereira V, Nadeem S, Valania G, Goldsweig AM. The Efficacy and Safety of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. Am J Cardiol. 2025 Apr 15; 241:52-60.

View in: PubMed
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Kulac I, Lee MMY, Lewis GD, Ma CS, Michels M, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins HC, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Olivotto I. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1821-1831.

View in: PubMed
Sherrod CF, Saberi S, Nassif ME, Claggett BL, Coats CJ, Garcia-Pavia P, Januzzi JL, Lewis GD, Ma C, Maron MS, Miao ZM, Olivotto I, Veselka J, Butzner M, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Spertus JA. Effect of Aficamten on Health Status?Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1773-1785.

View in: PubMed
Masri A, Cardoso RN, Abraham TP, Claggett BL, Coats CJ, Hegde SM, Kulac IJ, Lee MMY, Maron MS, Merkely B, Michels M, Olivotto I, Oreziak A, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Solomon SD, Wohltman A, Kwong RY, Kramer CM. Effect of Aficamten on Cardiac Structure?and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1806-1817.

View in: PubMed
Hegde SM, Claggett BL, Wang X, Jering K, Prasad N, Roshanali F, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Cardim N, Coats CJ, Kramer CM, Maron MS, Michels M, Olivotto I, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Meng L, Wohltman A, Malik FI, Solomon SD. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1789-1802.

View in: PubMed
Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Heart Assoc. 2024 Aug 06; 13(15):e035993.

View in: PubMed
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 05 30; 390(20):1849-1861.

View in: PubMed
Maron MS, Rowin EJ, Maron BJ. Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten? Asian Cardiovasc Thorac Ann. 2022 Jan; 30(1):11-18.

View in: PubMed
Maron MS, Ommen SR. Exploring New and Old Therapies for Obstructive Hypertrophic Cardiomyopathy: Mavacamten in Perspective. Circulation. 2021 03 23; 143(12):1181-1183.

View in: PubMed
Maron BJ, Rowin EJ, Maron MS. Is Regression of Left Ventricular Hypertrophy Really a Good Thing for Patients With Hypertrophic Cardiomyopathy?: The Emerging Mavacamten Story. Am J Cardiol. 2021 05 15; 147:145-146.

View in: PubMed

People

Explore

Similar Concepts

Top Journals